Search stocks

Find any stock by ticker or company name

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

О нас

Контакты

[email protected]

Мы в соцсетях

Instagram
Telegram
LinkedIn

Все права защищены.

Условия использования

Главная
Избранное
Рынки
Скринер
Новости
О нас

MASS - 908 Devices Inc. Последние новости | Finranks

Home

/

MASS

9

908 Devices Inc. (MASS)

NGM – Цена в реальном времени. Валюта: USD

8.78

-0.20 (-2.23%)

При закрытии: Jun 26, 2026, 4:00 PM EDT

8.75

-0.03 (-0.34%)

После закрытия: Jun 26, 2026, 5:53 PM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

908 Devices (MASS) Upgraded to Buy: Here's Why

908 Devices (MASS) Upgraded to Buy: Here's Why

908 Devices (MASS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

908 Devices Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

908 Devices Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

BURLINGTON, Mass.--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for vital health, safety and defense tech applications, announced that on June 1, 2026, the Compensation Committee of its Board of Directors granted options to four new non-executive employees to purchase an aggregate of 179,912 shares of 908 Devices' common stock. The options were granted as a material inducement to employment with 908 D.

908 Devices to Present at the 16th Annual East Coast IDEAS Investor Conference

908 Devices to Present at the 16th Annual East Coast IDEAS Investor Conference

BURLINGTON, Mass.--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for vital health, safety and defense tech applications, announced that CEO and Co-founder Kevin J. Knopp and CFO Joe Griffith will present and host investor meetings at the 16th Annual East Coast IDEAS Conference on Wednesday, June 10, 2026. The Company presentation is scheduled to begin at 8:35 a.m. Eastern Time. The presentation is webc.

908 Devices Looking Better Now (Rating Upgrade)

908 Devices Looking Better Now (Rating Upgrade)

908 Devices (MASS) delivered strong Q1 results, raising full-year revenue guidance after a strategic acquisition in narcotics detection. Adjusted gross margins improved nearly three percentage points to 57%, and operating cash flow turned positive. The company has a solid balance sheet with nearly $100 million in cash post-acquisition and is debt free, while trading at a reasonable valuation.

908 Devices Inc. (MASS) Q1 2026 Earnings Call Transcript

908 Devices Inc. (MASS) Q1 2026 Earnings Call Transcript

908 Devices Inc. (MASS) Q1 2026 Earnings Call Transcript

908 Devices Inc. (MASS) Reports Q1 Loss, Tops Revenue Estimates

908 Devices Inc. (MASS) Reports Q1 Loss, Tops Revenue Estimates

908 Devices Inc. (MASS) came out with a quarterly loss of $0.15 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.22 per share a year ago.

908 Devices Reports First Quarter 2026 Financial Results and Raises 2026 Revenue Outlook

908 Devices Reports First Quarter 2026 Financial Results and Raises 2026 Revenue Outlook

BURLINGTON, Mass.--(BUSINESS WIRE)-- #ChemicalID--908 Devices Inc. (Nasdaq: MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for vital health, safety and defense tech applications, today reported financial results for the quarter ended March 31, 2026. “We delivered a strong start to 2026, achieving 14% revenue growth and meaningful margin expansion,” said Kevin J. Knopp, CEO and Co-founder. “We are also excited to announce the acquisition of NIRLAB AG, a strate.

Видео

No Data

There is no data to display

Пресс-релизы

908 Devices Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

908 Devices Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

BURLINGTON, Mass.--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for vital health, safety and defense tech applications, announced that on June 1, 2026, the Compensation Committee of its Board of Directors granted options to four new non-executive employees to purchase an aggregate of 179,912 shares of 908 Devices' common stock. The options were granted as a material inducement to employment with 908 D.

908 Devices Reports First Quarter 2026 Financial Results and Raises 2026 Revenue Outlook

908 Devices Reports First Quarter 2026 Financial Results and Raises 2026 Revenue Outlook

BURLINGTON, Mass.--(BUSINESS WIRE)-- #ChemicalID--908 Devices Inc. (Nasdaq: MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for vital health, safety and defense tech applications, today reported financial results for the quarter ended March 31, 2026. “We delivered a strong start to 2026, achieving 14% revenue growth and meaningful margin expansion,” said Kevin J. Knopp, CEO and Co-founder. “We are also excited to announce the acquisition of NIRLAB AG, a strate.

908 Devices Acquires NIRLAB AG, Expanding Its Narcotics Detection Portfolio

908 Devices Acquires NIRLAB AG, Expanding Its Narcotics Detection Portfolio

BURLINGTON, Mass.--(BUSINESS WIRE)-- #LawEnforcement--908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld devices for chemical analysis, announces that it has completed the acquisition of NIRLAB AG, a privately held company based in Lausanne, Switzerland. The company delivers AI-powered, cloud-connected near-infrared (NIR) spectroscopy to perform handheld chemical analysis of narcotics in seconds. This acquisition expands 908 Devices' analytical portfolio and strengthens its leadership in narcot.

908 Devices Appoints Kola Otitoju as Chief Business & Strategy Officer and Announces an Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

908 Devices Appoints Kola Otitoju as Chief Business & Strategy Officer and Announces an Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

BURLINGTON, Mass.--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld devices for chemical analysis, announces the appointment of Kola Otitoju as its Chief Business & Strategy Officer, a newly created executive position. Mr. Otitoju will oversee product and corporate strategy, business development, mergers and acquisitions, and partnership initiatives as 908 Devices expands its market presence across public health, safety, and defense-tech applications. Mr.